Hallucinogen use disorders among adult users of MDMA and other hallucinogens

American Journal on Addictions

Volumn 17, Issue 5, 2008, Pages 354-363

  Wu, Li Tzy ^a,c   Ringwalt, Christopher L ^b   Mannelli, Paolo ^a   Patkar, Ashwin A ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PACIFIC INSTITUTE FOR RESEARCH AND EVALUATION   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; LYSERGIDE; MESCALINE; PSYCHEDELIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE CLASSIFICATION; DRUG DEPENDENCE; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; MALE; PREVALENCE;

ADOLESCENT; ADULT; CHILD; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HALLUCINOGENS; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PREVALENCE; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 51149107620     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490802269064     Document Type: Article

References (53)

1. Substance Abuse and Mental Health Services Administration. Results from the 2006 National Survey on Drug Use and Health: National Findings. Rockville, Md.: Office of Applied Studies, Substance Abuse and Mental Health Services; 2007.
2. National Institute on Alcohol Abuse and Alcoholism, 2007. National Epidemiologic Survey on Alcohol and Related Conditions, Survey Questionnaire Index, Wave 1. Available at: http://niaaa.census.gov/questionaire.html. Accessed October 15, 2007.
3. Cregg MT, Tracey JA. Ecstasy abuse in Ireland. Ir Med J. 1993;86:118-120.
4. Patel MM, Wright DW, Ratcliff JJ, Miller MA. Shedding new light on the "safe" club drug: Methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med. 2004;11:208-210.
5. Schifano F, Oyefeso A, Corkery J, et al. Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002. Hum Psychopharmacol. 2003;18:519-524.
6. Schuster P, Lieb R, Lamertz C, Wittchen HU. Is the use of ecstasy and hallucinogens increasing? Results from a community study. Eur Addict Res. 1998;4:75-82.
7. Wilkins C, Bhatta K, Pledger M, Casswell S. Ecstasy use in New Zealand: Findings from the 1998 and 2001 National Drug Surveys. N Z Med J. 2003;116:U383.
8. Substance Abuse and Mental Health Services Administration. Club Drugs, 2001 Update. Rockville, Md.: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2001.
9. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings. NIH Publication No. 07-6202. Bethesda, Md.: National Institute on Drug Abuse; 2007.
10. Montoya AG, Sorrentino R, Lukas SE, Price BH. Long-term neuropsychiatric consequences of "ecstasy" (MDMA): A review. Harv Rev Psychiatry. 2002;10:212-220.
11. Parrott AC. Human psychopharmacology of ecstasy (MDMA): A review of 15 years of empirical research. Hum Psychopharmacol. 2001;16:557-577.
12. National Institute on Drug Abuse, 2006. MDMA (Ecstasy) Abuse. NIDA Research Report Series. Available at: http://www.drugabuse.gov/PDF/RRmdma.pdf. Accessed October 15, 2007.
13. Gudelsky GA, Yamamoto BK. Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopamineric, serotonergic and cholinergic neurons. Pharmacol Biochem Behav. 2008;90:198-207 [E-pub].
14. Reneman L, Booij J, Majoie CB, Van Den Brink W, Den Heeten GJ. Investigating the potential neurotoxicity of ecstasy (MDMA): An imaging approach. Hum Psychopharmacol. 2001;16:579-588.
15. Klugman A, Gruzelier J. Chronic cognitive impairment in users of 'ecstasy' and cannabis. World Psychiatry. 2003;2:184-190.
16. Boyd CJ, McCabe SE, d'Arcy H. Ecstasy use among college undergraduates: Gender, race and sexual identity. J Subst Abuse Treat. 2003;24:209-215.
17. Klitzman RL, Greenberg JD, Pollack LM, Dolezal C. MDMA ('ecstasy') use, and its association with high risk behaviors, mental health, and other factors among gay/bisexual men in New York City. Drug Alcohol Depend. 2002;66:115-125.
18. Strote J, Lee JE, Wechsler H. Increasing MDMA use among college students: Results of a national survey. J Adolesc Health. 2002;30:64-72.
19. Baker A, Kochan N, Dixon J, Wodak A, Heather N. Drug use and HIV risk-taking behaviour among injecting drug users not currently in treatment in Sydney, Australia. Drug Alcohol Depend. 1994;34:155-160.
20. Rickert VI, Siqueira LM, Dale T, Wiemann CM. Prevalence and risk factors for LSD use among young women. J Pediatr Adolesc Gynecol. 2003;16:67-75.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text rev. Washington, DC: American Psychiatric Association; 2000.
22. Anthony JC, Warner, LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol. 1994;2:244-268.
23. Compton WM, Conway KP, Stinson FS, Colliver JD, Grant BF. Prevalence, correlates, and comorbidity of DSM-IV antisocial personality syndromes and alcohol and specific drug use disorders in the United States: Results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry. 2005;66:677-685.
24. Grant BF. DSM-IV, DSM-III-R, and ICD-10 alcohol and drug abuse/harmful use and dependence, United States, 1992: A nosological comparison. Alcohol Clin Exp Res. 1996;20:1481-1488.
25. Stone AL, Storr CL, Anthony JC. Evidence for a hallucinogen dependence syndrome developing soon after onset of hallucinogen use during adolescence. Int J Methods Psychiatr Res. 2006;15:116-130.
26. Pedersen W, Skrondal A. Ecstasy and new patterns of drug use: A normal population study. Addiction. 1999;94:1695-1706.
27. Topp L, Hando J, Dillon P, Roche A, Solowij N. Ecstasy use in Australia: Patterns of use and associated harm. Drug Alcohol Depend. 1999;55:105-115.
28. Yacoubian GS Jr. Correlates of ecstasy use among students surveyed through the 1997 College Alcohol Study. J Drug Educ. 2003;33:61-69.
29. Cottler LB, Womack SB, Compton WM, Ben-Abdallah A. Ecstasy abuse and dependence among adolescents and young adults: Applicability and reliability of DSM-IV criteria. Hum Psychopharmacol. 2001;16:599-606.
30. Saunders JB. Substance dependence and non-dependence in the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the International Classification of Diseases (ICD): Can an identical conceptualization be achieved? Addiction. 2006;101:48-58.
31. Degenhardt L, Lynskey M, Coffey C, Patton G. 'Diagnostic orphans' among young adult cannabis users: Persons who report dependence symptoms but do not meet diagnostic criteria. Drug Alcohol Depend. 2002;67:205-212.
32. Substance Abuse and Mental Health Services Administration. Results from the 2005 National Survey on Drug Use and Health: National Findings. Rockville, Md.: Office of Applied Studies, Substance Abuse and Mental Health Services; 2006.
33. Turner CF, Ku L, Rogers SM, Lindberg LD, Pleck JH, Sonenstein FL. Adolescent sexual behavior, drug use, and violence: Increased reporting with computer survey technology. Science. 1998;280:867-873.
34. Shiffman S, Waters AJ, Hickcox M. The Nicotine Dependence Syndrome Scale: A multi-dimensional measure of nicotine dependence. Nicotine Tob Res. 2004;6:327-348.
35. Fagerstrom KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav. 1978;3:235-241.
36. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction. 1991;86:1119-1127.
37. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-627.
38. Wu LT, Schlenger WE, Galvin DM. Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths. Drug Alcohol Depend. 2006;84:102-113.
39. Wu LT, Pilowsky DJ, Wechsberg WM, Schlenger WE. Injection drug use among stimulant users in a national sample. Am J Drug Alcohol Abuse. 2004;30:61-83.
40. Wu LT, Pilowsky DJ, Patkar AA. Non-prescribed use of pain relievers among adolescents in the United States. Drug Alcohol Depend. 2008;94:1-11.
41. Research Triangle Institute. SUDAAN User's Manual, Release 9.0. Research Triangle Park, NC: Research Triangle Institute; 2006.
42. Hasin DS, Hatzenbueler M, Smith S, Grant BF. Co-occurring DSM-IV drug abuse in DSM-IV drug dependence: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2005;80:117-123.
43. Helzer JE, van den Brink W, Guth SE. Should there be both categorical and dimensional criteria for the substance use disorders in DSM-V? Addiction. 2006;101:17-22.
44. Jansen KL. Ecstasy (MDMA) dependence. Drug Alcohol Depend. 1999;53:121-124.
45. Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E. Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology (Berl). 2004;173:398-404.
46. Lieb R, Schuetz CG, Pfister H, von Sydow K, Wittchen H. Mental disorders in ecstasy users: A prospective-longitudinal investigation. Drug Alcohol Depend. 2002;68:195-207.
47. Medina KL, Shear PK. Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: Contributions of polydrug use. Drug Alcohol Depend. 2007;87:303-311.
48. Soar K, Turner JJ, Parrott AC. Problematic versus non-problematic ecstasy/MDMA use: The influence of drug usage patterns and pre-existing psychiatric factors. J Psychopharmacol. 2006;20:417-424.
49. Hendrickson JC, Gerstein DR. Criminal involvement among young male ecstasy users. Subst Use Misuse. 2005; 40:1557-1575.
50. Gfroerer J, Wright D, Kopstein A. Prevalence of youth substance use: The impact of methodological differences between two national surveys. Drug Alcohol Depend. 1997;47:19-30.
51. Thomasius R, Petersen KU, Zapletalova P, Wartberg L, Zeichner D, Schmoldt A. Mental disorders in current and former heavy ecstasy (MDMA) users. Addiction. 2005;100:1310-1319.
52. Baggott M, Heifets B, Jones RT, Mendelson J, Sferios E, Zehnder J. Chemical analysis of ecstasy pills. JAMA. 2000;284:2190.
53. Parrott AC. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology (Berl). 2004;173:234-241.